Harbor Capital Advisors Inc. Sells 15,822 Shares of Haemonetics Co. (NYSE:HAE)

Harbor Capital Advisors Inc. lowered its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 31.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,532 shares of the medical instruments supplier's stock after selling 15,822 shares during the period. Harbor Capital Advisors Inc. owned about 0.07% of Haemonetics worth $2,195,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Empowered Funds LLC acquired a new position in Haemonetics in the fourth quarter valued at about $319,000. Allspring Global Investments Holdings LLC boosted its position in Haemonetics by 0.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier's stock valued at $62,802,000 after buying an additional 5,668 shares in the last quarter. Van ECK Associates Corp acquired a new position in Haemonetics in the fourth quarter valued at about $3,094,000. Vontobel Holding Ltd. boosted its position in Haemonetics by 166.7% in the fourth quarter. Vontobel Holding Ltd. now owns 13,011 shares of the medical instruments supplier's stock valued at $1,016,000 after buying an additional 8,133 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Haemonetics by 0.6% in the fourth quarter. Rhumbline Advisers now owns 159,262 shares of the medical instruments supplier's stock valued at $12,435,000 after buying an additional 1,024 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Trading Down 1.9%

Shares of HAE traded down $1.34 on Friday, reaching $70.02. 289,017 shares of the company's stock were exchanged, compared to its average volume of 677,894. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $3.36 billion, a P/E ratio of 27.57, a price-to-earnings-growth ratio of 1.11 and a beta of 0.36. The business has a 50 day moving average price of $65.16 and a two-hundred day moving average price of $69.04. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $94.99.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.90 earnings per share. Research analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on HAE. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. JMP Securities reiterated a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Raymond James reiterated a "strong-buy" rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, Needham & Company LLC reduced their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $97.89.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.